PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES following Perry's acquisition of 46 Corvair discount auto parts stores. The acquisition of the Columbus, Ohio-based auto chain with annual sales of approximately $22 mil. will raise the number of auto stores operated by Perry to 150, compared with 143 drug stores, according to an Oct. 10 release announcing a definitive agreement between the two firms. The acquisition is the fifth by Perry in as many months, and the third purchase of an auto parts chain since June. Automotive sales are expected to account for as much as 22% of total sales for Perry in fiscal 1984, which ends Oct. 31, a company spokesman told "The Pink Sheet." Last year, net automotive sales were $40.1 mil., representing 14% of Perry's total net sales of $200.2 mil. Rx volume remains a key segment in Perry's sales mix, however. In 1983, Rx sales increased 35% to $56.4 mil., representing approximately 20% of total sales. Rx and automotive sales combined are expected to account for between 40% to 43% of total sales in fiscal 1984. According to a company spokesman, Perry's goal is for combined automotive and Rx sales to reach 50% of the chain's total sales within the next few years.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
